The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis.

Antoine MeyerJérémie RudantJérôme DrouinJoël CosteFranck CarbonnelAlain Weill

Published in: Alimentary pharmacology & therapeutics (2019)

The effectiveness of CT-P13 is equivalent and the risk of serious infections could be lower than that of the reference product for infliximab-naive patients with ulcerative colitis.

Keyphrases

ulcerative colitis
image quality
dual energy
computed tomography
contrast enhanced
randomized controlled trial
systematic review
positron emission tomography
magnetic resonance imaging
pet ct